The development of new HER2-directed therapies has resulted in a significant prolongation of survival for women with metastatic HER2-positive breast cancer. Discoveries in the laboratory inform clinical trials which are the basis for improving the standard of care and are also the backbone for quality improvement. Clinical trials can be completed more rapidly by expanding trial enrollment to community sites. In this article we review some of the challenges in treating metastatic breast cancer with HER2-directed therapies and our strategies for incorporating our community partners into the research network.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355741 | PMC |
| http://dx.doi.org/10.3390/jcm9061984 | DOI Listing |
Publication Analysis
Top Keywords
breast cancer
12
metastatic breast
8
her2-directed therapies
8
clinical trials
8
her2-directed therapy
4
therapy metastatic
4
cancer community
4
community physicians
4
physicians collaborate
4
collaborate improve
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!